This article is more than 5 years old. Information may no longer be current.

Bausch + Lomb submits NDA for Vesneo

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb has submitted a new drug application for Vesneo to the FDA, Nicox announced in a press release.

Vesneo (latanoprostene bunod ophthalmic solution 0.024%) is a once-daily IOP-lowering single-agent eye drop for patients with open-angle glaucoma or ocular hypertension.

The data in the NDA support Vesneo as the first nitric-oxide donating agent for ophthalmic use, the release said.